A multicentre randomised controlled trial assessing whether MRI-targeted biopsy is non-inferior to standard transrectal ultrasound guided biopsy for the diagnosis of clinically significant prostate cancer in men without prior biopsy: a study protocol

Veeru Kasivisvanathan,1,2 Fatima Jichi,3 Laurence Klotz,4 Arnauld Villers,5 Samir S Taneja,6 Shonit Punwani,7,8 Alex Freeman,9 Mark Emberton,1,2 Caroline M Moore1,2

To cite: Kasivisvanathan V, Jichi F, Klotz L, et al. A multicentre randomised controlled trial assessing whether MRI-targeted biopsy is non-inferior to standard transrectal ultrasound guided biopsy for the diagnosis of clinically significant prostate cancer in men without prior biopsy: a study protocol. BMJ Open 2017;7:e017863. doi:10.1136/bmjopen-2017-017863

Abstract

Introduction The classical pathway for the diagnosis of prostate cancer is transrectal ultrasound-guided (TRUS) biopsy of the prostate initiated on the basis of a raised prostate-specific antigen (PSA). An alternative pathway is to perform multi-parametric MRI (MPMRI) to localise cancer and to use this information to influence the decision for, and conduct of, a subsequent biopsy, known as an MPMRI-targeted biopsy. An MPMRI pathway has been shown to detect a similar or greater amount of clinically significant cancer as TRUS biopsy but has several advantages, including the potential to biopsy fewer men with fewer cores.

Methods This is a pragmatic, international, multicentre, parallel group randomised study in which men are allocated in a 1:1 ratio to an MPMRI or TRUS biopsy pathway. This study will assess whether an MPMRI-targeted biopsy approach is non-inferior to a standard TRUS biopsy approach in the diagnosis of clinically significant cancer. Men in the MRI arm will undergo targeted biopsy of suspicious areas only and no biopsy will be carried out if the MRI is non-suspicious. Men in the TRUS biopsy will undergo a standard 10–12-core TRUS biopsy. The primary outcome is the proportion of men with clinically significant cancer detected. A sample size of at least 470 patients is required. Key secondary outcomes include the proportion of clinically insignificant cancer detected.

Ethics and dissemination Ethical approval was obtained from the National Research Ethics Committee East Midlands, Leicester (15/EM/0188). Results of this study will be disseminated through national and international papers. The participants and relevant patient support groups will be informed about the results of the study.

Registration details NCT02380027; Pre-results

Strengths and limitations of this study

- Randomised trial which mitigates bias and reduces chances of observed outcome being influenced by confounding factors.
- International multicentre study making results more generalisable.
- Pragmatic design making results more applicable to real life clinical practice, thus results can be used to change clinical practice.
- Pragmatic design introducing more variability in trial interventions.

Study title

Long study title: A multicentre randomised controlled trial assessing whether magnetic resonance imaging-targeted biopsy is non-inferior to standard transrectal ultrasound guided biopsy for the diagnosis of clinically significant prostate cancer in men without prior biopsy

Short study title: PRostate Evaluation for Clinically Important disease: Sampling using Image-guidance Or Not? (PRECISION)

Study Acronym: PRECISION

Introduction

Prostate cancer is the most common male cancer in Europe with an incidence of 370 000 new cases per year and an incidence in the USA of 161 360 new cases per year.1 2 It is the second most common cause of cancer death in European men, with 90 000 deaths per year in Europe and 26 730 deaths per year in the...
USA. A major unmet need in prostate cancer care is to better identify men who will benefit from treatment while avoiding overtreatment of men who are unlikely to benefit.

The classical pathway for the diagnosis of prostate cancer is transrectal ultrasound-guided (TRUS) biopsy of the prostate following a raised prostate-specific antigen (PSA). TRUS guidance is performed primarily for anatomical guidance and the ultrasound discriminates poorly between cancerous and non-cancerous tissues. Biopsies are concentrated in areas of the peripheral zone, thought to harbour the majority of cancers.

An alternative pathway for the diagnosis of prostate cancer in men with raised PSA is to perform a multi-parametric MRI (MPMRI) to localise cancer and to use this information to influence both the decision for and conduct of a subsequent biopsy, known as an MPMRI-targeted biopsy. MPMRI has demonstrated good diagnostic performance for the detection of clinically significant cancer. MPMRI-targeted biopsy has been shown to detect a similar or greater amount of clinically significant cancer to TRUS biopsy but avoid the detection of a greater proportion of clinically insignificant cancer, which may not benefit from treatment. Robust level 1 evidence from appropriately powered studies comparing MPMRI-targeted biopsy to TRUS biopsy in a pragmatic multicentre setting is lacking.

If MPMRI-targeted biopsy leads to fewer men being biopsied with fewer biopsy cores, no fewer clinically significant cancers identified but fewer insignificant cancers identified, then an MPMRI-driven diagnostic pathway could replace TRUS biopsy as the standard of care for prostate cancer diagnosis.

Objectives
The primary objective is to assess whether MPMRI-targeted biopsy is non-inferior to standard 10–12-core TRUS biopsy in the diagnosis of clinically significant prostate cancer in men referred with clinical suspicion of prostate cancer who have had no prior prostate biopsy.

Key secondary objectives include:
- To assess whether MPMRI-targeted biopsy detects fewer men with clinically insignificant prostate cancer than 10–12-core TRUS biopsy
- To assess the proportion of men in the MRI arm who avoid biopsy

Trial design
This is a pragmatic, international, multicentre, parallel group, non-inferiority randomised study in which men are allocated in a 1:1 ratio to MPMRI or to TRUS biopsy. This is the first trial to randomise men to an MRI arm in which targeted biopsy alone is carried out in the presence of an MRI lesion (ie, no biopsies of MRI-normal areas of prostate) and in which no biopsy at all is carried out if the MRI is non-suspicious (figure 1). The comparator of TRUS biopsy has been chosen as this is currently the standard of care in the majority of institutions.

A randomised trial design was chosen rather than a paired cohort design for the following reasons:
- In order to reduce performance bias that can result from carrying out one test after another as the conduct of one test may influence conduct of the other when both are carried out in the same patient.
- To allow the assessment of adverse events (AEs) associated with each technique.
- To allow the assessment of the patient’s willingness to remain on their allocated pathway.
- To allow the assessment of the physician’s willingness to adhere to the allocated pathway.
- To allow patients to potentially benefit by having a biopsy with fewer biopsy cores.
- To allow patients to potentially benefit by avoiding a biopsy and its complications altogether.

There is no gold standard reference test that is applicable to all patients referred with suspected prostate cancer. As radical prostatectomy is only performed in a small proportion of patients who test positive on the index test, it is therefore not an appropriate reference test. Therefore, a comparison of cancer detection between each approach was chosen as the primary outcome of interest.

METHODS AND ANALYSIS
Study setting
Hospitals which perform MPMRI-targeted and TRUS biopsy will take part in the study. Some of these centres will be from the Standards of Reporting for MRI-targeted Biopsy Studies (START) consortium, though non-START consortium centres are permitted to take part providing prior detection rates from the biopsy procedures in their practice are approved by the chief investigator prior to starting the study at their centre.

We expect centres from the following countries to take part: Argentina, Belgium, Canada, Finland, France, Italy, Germany, the Netherlands, Switzerland, UK and the USA.

Eligibility criteria
Patients will be considered eligible for registration into this study if they fulfil all of the inclusion criteria and none of the exclusion criteria, as defined in box 1. The key eligibility criteria include serum PSA ≤20 ng/mL, suspected tumour stage ≤T2 on rectal examination and no prior prostate biopsy.

Interventions
MPMRI arm
MPMRI will be carried out using a 1.5 Tesla or 3.0 Tesla scanner with a pelvic phased array coil and power injector for contrast administration with the patient in the supine position. T2-weighted, diffusion weighted and dynamic contrast enhanced scans will be acquired as per the minimum requirements set out by consensus guidelines. The site performing the MPMRI should provide specific detailed information on their MRI scanners and
protocols in advance which need to be approved by the PRECISION Operations Group prior to participating in the study.

The MPMRI will be reported by an experienced nominated radiologist using a dedicated MRI reporting pro forma. Prior experience of the radiologists must be provided in advance and approved by the PRECISION Operations Group prior to the site being able to participate in the study. The MPMRI will be scored based on consensus recommendations\(^8\) employing a 1–5 score of suspicion:

- 1 = Highly unlikely to be clinically significant cancer
- 2 = Unlikely to be clinically significant cancer
- 3 = The presence of clinically significant cancer is equivocal
- 4 = Likely to be clinically significant cancer
- 5 = Highly likely to be clinically significant cancer

**MPMRI-targeted biopsy**

A participant with a prostate that contains a suspicious area with an MPMRI score of 3, 4 or 5 will subsequently undergo targeted biopsy by a clinician experienced in MPMRI-targeted biopsy. The experience of the clinicians performing biopsy must be provided to the PRECISION Operations Group in advance and approved prior to the site participating in the study.

A maximum of three MRI-suspicious areas will be chosen for targeted biopsy with a maximum of 4 cores to be taken per suspicious area and a maximum of 12 cores in total. Targeted biopsies can be performed by visual registration or software-assisted registration, as described in advance and approved by the PRECISION Operations Group prior to the site being able to participate in the study.
previously, and can be carried out transrectally or transperineally, according to local expertise.

**No target identified on MPMRI**
A participant with a prostate that contains no suspicious areas on MPMRI (ie, scoring 1 or 2) will not undergo a biopsy as part of the protocol.

**TRUS biopsy arm**
All participants in this arm will undergo a standard 10–12-core TRUS biopsy as described previously. The patient will be positioned in the left lateral position and 10–12 cores will be taken from the peripheral zone of the apex, mid-gland and base of the prostate on the right and left sides.

The experience of the clinicians performing the biopsy must be provided to the PRECISION Operations Group in advance and approved prior to the site participating in the study.

**Patient-reported outcome measures**
In both arms self-reported questionnaires to capture biopsy-specific side effects will be completed immediately postprocedure, and at 30 days. Health-related quality of life EQ-5D-5L questionnaires will also be completed at baseline, 24 hours post-MRI, 24 hours post biopsy and 30 days post intervention.

### Treatment decision and participant timeline
A clinician reviews participants with results of the test and treatment decisions are made according to local standard of care. If a further biopsy, further MPMRI or any other diagnostic test is requested from the treatment decision visit or if the clinician books a radical prostatectomy, then the result of the procedure is recorded, after which the man completes the study. Otherwise men complete the study after the treatment decision visit or when the 30-day questionnaires are completed, whichever is later.

Providing the interventions occur in the specified sequence order, there is no necessitated timeline within which the interventions must occur as this is dependent on local resources, but it is expected that the majority of patients will complete the study within 6 weeks of enrolment (table 1A,B,C).

### Interventions—strategies to improve adherence to intervention protocols
After the treatment decision has been made, clinicians are permitted to order the test that the patient was not randomised to and participants are aware of this when enrolling in the study.

| Table 1A  | Participant timeline in the study: the timeline for men randomised to TRUS biopsy |
|-----------|----------------------------------------------------------------------------------|
| Contact with patient | Visit 0* | Visit 1 | Visit 2 | Visit 3 | Visit 4 |
| Weeks: | −1 | 0 | 1 | 2 | 6 |
| Teleconsult | X | | | | |
| Consent | | X | | | |
| Screening | | | X | | |
| Randomisation | | | | X | |
| EQ-5D-5L | | X | | X | |
| Optional urine, blood and semen samples | | | X | | |
| TRUS biopsy | | | | X | |
| MRI | | | | | |
| MPMRI-targeted biopsy | | | | | |
| Immediate post-MRI questionnaire | | | | | |
| Immediate post biopsy questionnaire | | | X | | |
| Follow-up for results of tests | | | | X | |
| Treatment decision† | | | | X | |
| 30-day post biopsy questionnaire | | | | X | |
| 30-day post-MRI questionnaire | | | | | |
| SAE | Complete as required at any time following registration |
| Withdrawal form | Complete as required at any time following registration |

*This visit is optional depending on local site referral procedures. It is carried out over the phone 1 week prior to the first face-to-face visit.
†After treatment decision men revert to standard of care.

MPMRI, multi-parametric MRI; SAE, serious adverse event, TRUS, transrectal ultrasound-guided.
Participants are given reminders by the trial teams for completion of questionnaires at the correct time.

**Interventions—concomitant care**

Relevant anticoagulant/antiplatelet medication will be discontinued up to 10 days before biopsy and advice sought as to appropriate substitutes if indicated. Aspirin will be continued at the discretion of the physician doing the biopsy.

Participants may otherwise continue with any other concomitant care that they were receiving prior to enrolling on the study.

**Withdrawal of individual participants**

Participants can discontinue the participation of the study at any time for any reason. Data up to the time of withdrawal can be included in the study.

**Outcomes**

**Primary outcome**

Proportion of men with clinically significant cancer detected. This will be evaluated on a per patient basis from needle biopsy. The primary definition will be a single core containing Gleason grade 3+4 disease or greater.

Time frame for assessment: when histology results are available, at an expected average of 30 days post intervention.

**Secondary outcomes**

Please see table 2 for a full list of secondary outcomes.

**Sample size**

Rates of clinically significant cancer detection from targeted-alone biopsy in a population with no prior biopsy have been shown to be 50%. Assuring 20% of men avoid biopsy in the MRI arm of PRECISION, this would correspond to a 50% detection rate in 80% of the participants in this arm =40% overall detection rate of clinically significant cancer in the MRI arm.

Rates of clinically significant cancer detection from one of the largest studies of TRUS biopsy in men without prior biopsy are shown to be 27%. For the non-inferiority hypothesis, using 90% power and 2.5% one-sided α, using an estimate for detection rate of clinically significant cancer for targeted biopsy of 40% and an estimate of detection rate for TRUS biopsy of 30% and using a margin of clinical unimportance of 5%, 211 men per arm will be required. The choice of 5% as the margin of non-inferiority represents a difference that would be considered clinically unimportant in the detection rates.

Thus the total men required in the study is 422.

Accounting for 10% withdrawal/loss to follow-up, 470 men will need to be recruited.

---

**Table 1B** Participant timeline in the study: the timeline for men randomised to MPMRI who require an MPMRI-targeted biopsy

| Contact with patient | Visit 0* | Visit 1 | Visit 2 | Visit 3 | Visit 4 |
|----------------------|----------|---------|---------|---------|---------|
| Teleconsult          |          | X       |         |         |         |
| Consent              |          | X       |         |         |         |
| Screening            |          | X       |         |         |         |
| Randomisation        |          | X       |         |         |         |
| EQ-5D-5L             | X        | X       | X       |         | X       |
| Optional urine, blood and semen samples | X |
| TRUS biopsy          |          | X       |         |         |         |
| MRI                  |          | X       |         |         |         |
| MPMRI-targeted biopsy|          | X       |         |         |         |
| Immediate post-MRI questionnaire | X |
| Immediate post biopsy questionnaire | X |
| Follow-up for results of tests | X |
| Treatment decision† | X |
| 30-day post biopsy questionnaire | X |
| 30-day post-MRI questionnaire | X |

SAE Complete as required at any time following registration

Withdrawal form Complete as required at any time following registration

*This visit is optional depending on local site referral procedures. It is carried out over the phone 1 week prior to the first face-to-face visit.

†After treatment decision men revert to standard of care.

MPMRI, multi-parametric MRI; SAE, serious adverse event; TRUS, transrectal ultrasound-guided.
## Table 1C  
### Participant timeline in the study: the timeline for men randomised to MPMRI who have no suspicious areas on MRI and do not require a biopsy

| Contact with patient | Visit 0* | Visit 1 | Visit 2 | Visit 3 | Visit 4 |
|----------------------|----------|---------|---------|---------|---------|
| Weeks:               | −1       | 0       | 1       | 2       | 5       |
| Teleconsult          | X        |         |         |         | Not required |
| Consent              | X        |         |         |         |         |
| Screening            | X        |         |         |         |         |
| Randomisation        | X        |         |         |         |         |
| EQ-5D-5L             | X        | X       |         | X       |         |
| Optional urine, blood and semen samples | X | | | | |
| TRUS biopsy          |          |         |         |         |         |
| MRI                  |          |         |         |         | X       |
| MPMRI-targeted biopsy|          |         |         |         |         |
| Immediate post-MRI questionnaire | X | | | | |
| Immediate post biopsy questionnaire | | | | | |
| Follow-up for results of tests | | | | X | |
| Treatment decision† | | | | | X |
| 30-day post biopsy questionnaire | | | | X | |
| 30-day post-MRI questionnaire | | | | X | |
| SAE                  | Complete as required at any time following registration |
| Withdrawal form      | Complete as required at any time following registration |

*This visit is optional depending on local site referral procedures. It is carried out over the phone 1 week prior to the first face-to-face visit.
†After treatment decision men revert to standard of care.

MPMRI, multi-parametric MRI; SAE, serious adverse event, TRUS, transrectal ultrasound-guided.

### Table 2  
#### Secondary outcomes in PRECISION

| Outcome                                                                 | Time frame for assessment                                      |
|------------------------------------------------------------------------|----------------------------------------------------------------|
| Proportion of men with clinically insignificant cancer (Gleason grade 3+3) detected | When histology results available, at an expected average of 30 days post intervention |
| Proportion of men in the MPMRI arm who avoid biopsy                     | When MRI results available, at an expected average of 30 days post-MRI |
| Proportion of men in whom the MPMRI score for suspicion of clinically significant cancer was 3, 4 or 5 but no clinically significant cancer was detected | When histology results available, at an expected average of 30 days post biopsy |
| Proportion of men who go on to definitive local treatment (eg, radical prostatectomy, radiotherapy, brachytherapy) or systemic treatment (eg, hormone therapy, chemotherapy) | After treatment decision, at an expected average of 30 days post biopsy |
| Cancer core length of the most involved biopsy core (maximum cancer core length, mm) | When histology results available, at an expected average of 30 days post intervention |
| Proportion of men with post biopsy adverse events                        | 30 days post biopsy                                           |
| Health-related quality of life                                           | Baseline, 24 hours post intervention and 30 days post intervention |
| Proportion Gleason grade upgrading in men undergoing radical prostatectomy | An expected average of 90 days post biopsy                    |
| Cost per diagnosis of cancer                                            | 30 days post biopsy                                           |

MPMRI, multi-parametric MRI.

### Recruitment

Enrolment will take place at the outpatient clinics of the participating medical centres. Prior to being approved to take part in the study, participating sites are required to confirm that they have enough eligible patients attending their centre to be able to recruit approximately three
### Table 3  WHO trial registration data set

| Data category                          | Information                                                                 |
|----------------------------------------|-----------------------------------------------------------------------------|
| Primary registry and trial identifying number | ClinicalTrials.gov: NCT02380027                                              |
| Date of registration in the primary registry | 23 February 2015                                                            |
| Secondary identifying numbers          | ISRCTN: 18440098                                                            |
| Source(s) of monetary or material support | National Institute for Health and Research UK (DRF-2014-07-146)              |
|                                        | European Association of Urology Research Foundation                         |
| Primary sponsor                        | University College London                                                   |
| Secondary sponsor(s)                   | N/A                                                                         |
| Contact for public queries             | Mr Veeru Kasivisvanathan veeru.kasi@ucl.ac.uk Urology Research Group, Room 4.23, Fourth floor, 132 Hampstead Road, London, NW1 2PT Tel:+44 (0)207 679 9092, Fax:+44 (0)207 679 9511 |
| Contact for scientific queries         | Mr Veeru Kasivisvanathan veeru.kasi@ucl.ac.uk Urology Research Group, Room 4.23, Fourth floor, 132 Hampstead Road, London, NW1 2PT Tel:+44 (0)207 679 9092, Fax:+44 (0)207 679 9511 |
| Public title/short title               | Prostate evaluation for clinically important disease: sampling using image guidance or not? |
| Acronym                                | PRECISION                                                                   |
| Scientific title                       | A randomised control trial of MRI-targeted biopsy compared with standard TRUS biopsy for the diagnosis of prostate cancer in men without prior biopsy |
| Countries of recruitment               | Argentina, Belgium, Canada, Finland, France, Italy, Germany, Netherlands, Switzerland, UK, USA |
| Health condition(s) or problem(s) studied | Prostate neoplasm                                                         |
| Intervention(s)                        | Device: MRI. This will be a multi-parametric MRI of the prostate. Procedure: MRI-targeted biopsy. This will be a biopsy targeted to suspicious areas on the MRI. Procedure: TRUS biopsy. This will be a standard 12-core transrectal prostate biopsy. |
| Intervention description               | 1. Experimental: MRI-arm  
Men in this arm will undergo multi-parametric MRI. In the presence of a suspicious area, a man will undergo MRI-targeted biopsy with cores targeted to the suspicious lesion. In the absence of a suspicious area, no biopsy will be taken.  
Interventions:  
Device: MRI  
Procedure: MRI-targeted biopsy  
2. Active comparator: TRUS biopsy arm  
Men in this arm undergo standard 12-core TRUS prostate biopsy.  
Intervention:  
Procedure: TRUS biopsy |

Continued
### Key inclusion and exclusion criteria

**Inclusion criteria:**
1. Men at least 18 years of age referred with clinical suspicion of prostate cancer who have been advised to have a prostate biopsy
2. Serum PSA ≤20 ng/mL within the previous 3 months
3. Suspected stage ≤T2 on rectal examination (organ-confined prostate cancer) within the previous 3 months
4. Fit to undergo all procedures listed in the protocol
5. Able to provide written informed consent

**Exclusion criteria:**
1. Prior prostate biopsy
2. Prior treatment for prostate cancer
3. Contraindication to MRI (e.g., claustrophobia, pacemaker, estimated glomerular filtration rate ≤50 mls/min)
4. Contraindication to prostate biopsy
5. Men in whom artefact would reduce the quality of the MRI
6. Previous hip replacement surgery, metallic hip replacement or extensive pelvic orthopaedic metal work
7. Unfit to undergo any procedures listed in the protocol

### Study type

- Interventional
- Allocation: randomised
- Intervention model: parallel assignment
- Masking: statistician
- Primary purpose: diagnostic
- Sequence generation: bespoke SAS programme
- Block randomisation

Achievement of allocation concealment: only authorised staff members have access to the allocation sequence. No investigators have access to the sequence. The allocation for the next patient is given by an authorised staff member or electronically after the investigator confirms that the eligibility criteria for inclusion of that patient have been met.

### Date of first enrolment

10 February 2016

### Target sample size

470

### Recruitment status

Recruiting

### Primary outcome(s)

- Proportion of men with clinically significant detected cancer (time frame: when histology results are available, at an expected average of 30 days post biopsy)
- Proportion of men in the MRI arm who avoid biopsy (time frame: when MRI results are available, at an expected average of 30 days post-MRI)
- Proportion of men with an MRI score 3, 4 or 5 who have no clinically significant cancer detected (time frame: when histology results are available, at an expected average of 30 days post biopsy)
- Proportion of men who go on to definitive treatment for prostate cancer (time frame: after treatment decision, at an expected average of 30 days post biopsy)
- Definitive treatment can be localised (e.g., radical prostatectomy, radiotherapy, brachytherapy) or systemic (hormone therapy, chemotherapy)
- Cancer core length in mm of the most involved biopsy core (maximum cancer core length) (time frame: when histology results available, at an expected average of 30 days post biopsy)
- Proportion of men with post biopsy adverse events (time frame: 30 days post biopsy)
- EQ-5D-5L Quality of Life Scores (time frame: baseline, 24 hours post intervention and 30 days post intervention)
- Proportion of men undergoing radical prostatectomy who have Gleason grade upgrading (time frame: an expected average of 90 days post biopsy)
- Cost per diagnosis of cancer (time frame: 30 days post biopsy)

---

PSA, prostate-specific antigen; TRUS, transrectal ultrasound-guided.
men per month. With at least 11 participating centres, it is estimated that the study will complete within 26 months of commencement. The start date of the study is February 2016 and the estimated completion date for recruitment is April 2018.

**Randomisation and treatment allocation**
Participants are randomised in a 1:1 ratio to either MPMRI or TRUS biopsy. Randomisation will be executed per participant, by web-based block randomisation after the informed consent procedure is completed. The University College London (UCL) Surgical and Interventional Trials Unit will facilitate the randomisation.

**Sequence generation**
Randomisation schedules are be prepared by a member of the UCL Surgical and Interventional Trials Unit using a bespoke SAS programme, with equal allocation between treatment arms using random permuted blocks of varying size, stratified by centre.

**Allocation concealment**
Only authorised staff members within the UCL Surgical and Interventional Trials Unit and the authorised staff member who uploads the sequence to the web-based randomisation service have access to the allocation sequence. None of these staff members are involved in clinical patient contact. The investigators responsible for patient recruitment who do have clinical patient contact do not have access to the sequence and are unaware of the block sizes. The allocation for the next patient is given on a patient by patient basis by an authorised staff member or electronically by the web-based system.

**Blinding**
In this trial, blinding of the participant or the clinician is not feasible. While the study is progressing, for any clinical outcomes that come to the attention of the PRECISION Operations Group (e.g., serious adverse events (SAEs)), the main study statistician will be blinded as to which group these outcomes are from. Where feasible, when analysing the outcome data from the study, the study statistician will be blinded to the groups until the end of the analysis.

**Data management**
To ensure high quality trial conduct, data management will be carried out according to the principles of the International Council of Harmonisation Good Clinical Practice. Data will be entered onto a web-based MARVIN e-case report form (eCRF) system which increases data quality. Quality control is carried out routinely; data types, entries and permitted ranges for answers to every question on the eCRFs are restricted on this web-based system. Automatic validation checks and automatic queries are raised by the system immediately to individual sites in the case of any queries. Authorised individuals from the PRECISION Operations Group may also check the data for quality and may pose manual queries to the site to address. A proportion of participating sites’ MRI and histopathology data may be verified centrally.

### Table 4  Revision chronology for amendments to protocol

| Protocol version and date | Reasons for amendments                                                                 |
|--------------------------|----------------------------------------------------------------------------------------|
| V.1.0, issued 11 April 2015 | Main reasons for amendment: minor changes in the patient information sheet to ensure compliance with research ethics committee regulations. Main changes: 1. Version number and date added to all pages 2. Patient advice and liaison service contact details specified 3. Sentence changed from ‘different treatment’ to ‘a different diagnostic test’ 4. The name of the approving research ethics committee added ‘NRES Committee East Midlands - Leicester’ |
| V.1.1, issued 24 May 2015 | Main reasons for amendment: minor changes to make existing trial documents clearer. Main changes: 1. International Standard Registered Clinical/soCial sTudy Number (ICRCTN) number and UK Clinical Research Network(CRN) identifiers added. 2. Wording in Section 17.3 Assessment of Safety. Wording clarified to ensure it is clear which expected adverse events do not need to be reported. 3. Updates of sites and PIs participating in the trial. 4. Clarification in TRUS biopsy conduct section 11.2. TRUS biopsy as described in the protocol allows 10–12 cores to be taken. Although this was clear in the protocol, this is clarified throughout the text now as the procedure is often quoted as 12-core biopsy, which may otherwise be confusing to the PI. 5. Appendix 7—EQ-5D—update of copyright date from 1990 to 2009. No change in content. 6. In the ‘What will happen to me if I take part’ section, clarification that the timelines are suggested timelines and that timelines for trial procedures depend on clinical workload at the hospital. |
| V.1.2, issued 26 August 2015 | Main reasons for amendment: minor changes to make existing trial documents clearer. Main changes: 1. International Standard Registered Clinical/soCial sTudy Number (ICRCTN) number and UK Clinical Research Network(CRN) identifiers added. 2. Wording in Section 17.3 Assessment of Safety. Wording clarified to ensure it is clear which expected adverse events do not need to be reported. 3. Updates of sites and PIs participating in the trial. 4. Clarification in TRUS biopsy conduct section 11.2. TRUS biopsy as described in the protocol allows 10–12 cores to be taken. Although this was clear in the protocol, this is clarified throughout the text now as the procedure is often quoted as 12-core biopsy, which may otherwise be confusing to the PI. 5. Appendix 7—EQ-5D—update of copyright date from 1990 to 2009. No change in content. 6. In the ‘What will happen to me if I take part’ section, clarification that the timelines are suggested timelines and that timelines for trial procedures depend on clinical workload at the hospital. |

PI, principal investigator; TRUS, transrectal ultrasound-guided.
Table 5  Roles and responsibilities in the PRECISION Trial

| Role                      | Details and responsibilities                                                                                                                                 |
|---------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Trial sponsor             | University College London (UCL)<br>Sponsor’s reference: UCL REDA Number 15/0299<br>Contact name: Susan Tebbs<br>Address:<br>Comprehensive Clinical Trials Unit (CCTU)<br>UCL,<br>Gower Street,<br>London,<br>WC1E 6BT<br>Telephone: 020 3447 5557<br>Email: Rand.D@uclh.nhs.uk<br>The trial sponsor did not provide any funding for the study. University College London has the role of research governance sponsor of PRECISION. UCL adopted the study as sponsor after the UCL CCTU carried out a trial adoption process which involved the UCL CCTU reviewing the protocol to ensure it conformed to high standards of trial conduct and met the governance requirements of UCL. The UCL CCTU is responsible for oversight of the trial. The sponsor plays no role in data collection, management, analysis and interpretation of data, writing of the report or the decision to submit the report for publication. |
| PRECISION Operations Group | The PRECISION Operations Group consists of the chief investigators, the study coordinator, the UCL Surgical and Interventional Trials Unit and the eCRF database managers. This group is responsible for:<br► Study planning<br► Preparation of protocol and revisions<br► Assistance with international review board/independent ethics committee applications<br► Preparation of investigators brochure and CRFs<br► Organisation of steering committee meetings<br► Provide annual progress reports to the ethics committee<br► Reporting serious adverse events to the sponsor and ethics committee when necessary<br► Responsible for trial master file<br► Budget administration and contractual issues with individual centres<br► Advice for PIs<br► Site initiation visits<br► Randomisation<br► Data verification and management<br► Central monitoring and resolving data queries with clinicians and nurses at the trial sites<br► Maintenance of the trial Information Technology (IT) system<br► Publication of study reports |
| PI                        | At each participating site, the PI is responsible for the conduct of the clinical trial to ensure the safety of participants and the reliability and robustness of the data generated. They will be responsible for identification, recruitment, data collection and completion of CRFs, along with follow-up of study patients and adherence to study protocol and investigators brochure. The PI as leader of the research team may delegate his/her duties to members of his/her team. |
| GTSC                      | Consists of a team independent of the PRECISION Operations Group and independent of the PIs. It comprises independent chairs, advisory board members and chief investigators. Observers from the Clinical Trials Group are present during meetings. The GTSC’s role is to:<br>1. To monitor and supervise the progress of the study towards its overall objectives at regular intervals<br>2. To consider the recommendations of the DMC and make recommendations on future study conduct |
| DMC                       | Consists of an independent chair, clinical representative, patient representative and statistician. The DMC’s role is to safeguard the interests of trial participants and monitor the overall conduct of the clinical trial. The DMC is independent of, but reports to, the GTSC. |

CRF, case report form; DMC, Data Monitoring Committee; GTSC, Global Trial Steering Committee; PI, principal investigator.

The data will be stored by the PRECISION Operations Group for 20 years after the final publication from the trial. Further details on data storage, curation and destruction are available in a separate document on request to the UCL Surgical and Interventional Trials Unit.

Data collection methods
An eCRF user guide has been produced to aid sites in completing all eCRFs. Sites are required to confirm in writing that they have practised entering imaginary patient data for all eCRFs into a demo version of the
MARVIN eCRF system prior to being granted approval to use the live MARVIN eCRF system. Only authorised users of the system on the local site delegation log have access to the MARVIN system. Details on how to collect data in the study are given in a mandatory site initiation visit. The content of the presentation must be viewed by all local site staff.

Baseline patient and follow-up data will be recorded by authorised individuals from clinical encounters during the study. Self-reported, previously validated EQ-5D-5L questionnaires will be used to assess health-related quality of life. Post biopsy complications will be assessed by self-reported questionnaires based on previously validated questionnaires.

Participant retention
Once a participant is enrolled or randomised, the local site will make every reasonable effort to follow the patient for the entire study period. It is estimated that loss to follow-up/withdrawal after randomisation will be no more than 10%. Study site staff are responsible for developing and implementing local standard operating procedures to achieve this.

Statistical methods
The formal statistical analysis plan will be finalised before database lock and before any statistical analysis.

A consort diagram will be presented. All continuous variables will be described using the mean, SD, median, minimum and maximum. Categorical variables will be described using frequencies and proportions.

The statistical assumptions underpinning each method will be checked. The use of transformations or non-parametric methods will be considered to satisfy statistical assumptions.

Primary outcome analysis
The primary analysis will be based on an intention to treat sample as well as a per protocol sample.

Our primary end point is the difference in proportion of men with clinically significant cancer detected between the two groups.

Absolute differences in proportion of clinically significant cancer detected between arms will be calculated with 95% CIs.

If the lower bound of the 97.5% CI for the difference in detection rates of MPMRI+/− targeted biopsy compared with TRUS biopsy is greater than −5% then MPMRI+/− targeted biopsy will be deemed non-inferior.

In the event that the lower bound is greater than zero, superiority can be claimed.

Baseline characteristics will be compared between the two groups. Any imbalance found between the groups will be accounted for in a multivariable logistic regression analysis. This model will include clinically significant cancer as the dependant variable, group as the independent variable and any characteristics with baseline imbalance as a covariate. Potential confounders identified a priori will also be considered in the model described here. Here, the effect of centre will also be explored using a mixed logistic regression model with clinically significant cancer as the dependant variable, group as the independent variable and centre as a random effect.

The effect of missing data will be explored and dealt with in an appropriate manner.

Secondary outcome analyses
The effect sizes will be presented with 95% CIs.

For binary outcomes, absolute differences in proportion between arms will be calculated with 95% CIs. Any imbalance found between the groups will be accounted for in a multivariable logistic regression analysis.

For continuous outcomes, mean differences in outcomes between arms will be calculated with 95% CIs. Any imbalance found between the groups will be accounted for in a multivariable linear regression analysis. Where the outcomes are not normally distributed, a suitable transformation or non-parametric test will be considered.

Descriptive analysis
Where a patient after receiving the per protocol treatment receives another test which leads to further knowledge about the presence or absence of cancer, this will be described. The number of false positives and false negatives will be recorded.

Monitoring
The Global Trial Steering Committee (GTSC) consists of a team independent of the PRECISION Operations Group and independent of the principal investigators (PIs). It comprises chairs, advisory board members and chief investigators. Observers from the UCL Surgical and Interventional Trials Unit are present during meetings. The GTSC’s role is to:

1. To monitor and supervise the progress of the study towards its overall objectives at regular intervals
2. To consider the recommendations of the Data Monitoring Committee (DMC) and make recommendations on future study conduct

The DMC consists of an independent chair, clinical representative, patient representative and statistician. The DMC’s role is to safeguard the interests of trial participants and monitor the overall conduct of the clinical trial. The DMC is independent of, but reports to, the GTSC. They will meet at regular intervals throughout the study period as determined by the chair, but as a minimum at least once every 12 months.

The DMC Charter can be obtained by request to the Surgical and Interventional Trials Unit.

The sponsor may also arrange an independent trial monitor to audit the study data.

Harms
AEs will be defined as ‘any untoward medical occurrence in a clinical trial subject undergoing any intervention in
the trial, which does not necessarily have a causal relationship with this treatment’.

SAEs will be defined as ‘any untoward medical occurrence as a result of any intervention in the trial that:

► results in death,
► is life-threatening
► requires hospitalisation or prolongation of existing inpatients’ hospitalisation, results in persistent or significant disability or incapacity’

AEs and SAEs will be recorded until 30 days post biopsy. In the event that the patient does not undergo biopsy, AEs and SAEs should be recorded until 30 days post-MRI.

AEs will be recorded by a member of the research team or clinical team on an AE report form eCRF. All SAEs must be recorded on an SAE report form eCRF within 24 hours of knowledge of the SAE. Both AEs and SAEs should be recorded in the medical notes. Completed AE and SAE report forms should be sent to the UCL Surgical and Interventional Trials Unit, who will keep a log of AEs and SAEs. AE and SAE logs will be reviewed by the DMC.

Ethics and dissemination

The protocol and each participating site will have Research Ethics Committee (REC) approval before participants are entered. The UK National REC (NRES Committee East Midlands, Leicester) gave favourable approval for study on 3 June 2015 (Ref:15/EM/0188).

Amendments to the protocol will be made after ethical approval by the research ethics committee in each respective centre. Centres will be notified immediately after any protocol amendments.

Consent

The clinical teams managing patients with suspected prostate cancer who are referred to their centre will identify potential trial participants. Patient information sheets will be provided to patients. Members of staff who are trained to take written informed consent, as indicated by the PI on the delegation log for that site, will take written informed consent in a face-to-face visit. A model consent form is shown in online supplementary appendix 1 and a model patient information sheet is shown in online supplementary appendix 2.

Additional ethics-approved consent will be sought from patients for collection of biological samples (blood, urine, semen), pending additional funding being secured for collection and processing of samples. If funding is secured, these samples will be stored in the UCL/Royal Free Biobank for use in future biomarker studies (supplementary appendix 3).

Confidentiality

The data of the participants will be recorded into the eCRF system and analysed without any personal identifiers, by using coded information. The source documents and identification lists will be archived in a secured facility per centre. Permission for accessing data will be documented per investigator.

Dissemination

Results of this study will be disseminated through national and international conferences and papers. Authorship criteria will be based on recommendations of the International Committee of Medical Journal Editors. The participants and relevant patient support groups will be informed about the results of the study.

Access to data

Only authorised individuals within the PRECISION Operations Group have access to the final data set. Individual PIs have access to their own data but not that of other sites.

Declaration of interests

ME has stock holding in NUADA Medical (as a founder member). NUADA Medical is a healthcare company specialising in urology and gynaecology. They provide a range of imaging including MRI of the prostate. The PRECISION Operations Group reports no other interests to declare. Declaration of interests will be ascertained from each PI participating in the study and reported in full on dissemination of study results.

WHO trial registration data set

For the WHO trial registration data set please see table 3.

Current protocol version

The current protocol is V.1.2, issued 26 August 2015. The current protocol amendment number is 02. For full amendment history please see table 4.

Funding

This work was funded by a doctoral research fellowship for VK from the National Institute for Health Research (DRF-201407-146). UK sites are funded by inclusion of the study in the NIHR portfolio (UKCRN ID 18902 PRECISION). Non-UK sites are funded by the European Association of Urology Research Foundation (EAURF2015001). The design, management, analysis and reporting of the study are entirely independent of the funders of the study.

Roles and responsibilities

For roles and responsibilities of the trial sponsor and committees involved in the study, see table 5.

Author affiliations

1Division of Surgery and Interventional Science, University College London, London, UK
2Department of Urology, University College London Hospital, London, UK
3Biostatistics Group, Joint Research Office, University College London and University College London Hospital, London, UK
4Department of Urology, Sunnybrook Hospital, Toronto, Canada
5Department of Urology, CHU Lille, University Lille Nord de France, Lille, France
6Department of Urology, New York University Langone Medical Centre, New York City, New York, USA
7Centre for Medical Imaging, University College London, London, UK
8Department of Radiology, University College London Hospital, London, UK
9Department of Pathology, University College London Hospital, London, UK

Acknowledgements

The authors thank the UCL Surgical and Interventional Trials Unit and the UCL Comprehensive Clinical Trials Unit for reviewing the
protocol and recommending changes as part of their approval process in setting up the PRECISION study. The authors also thank the START Consortium for their contribution in the discussion of the study design and other aspects of the protocol, especially, Richard Simon, who provided important statistical and methodological advice.

Contributors All authors have made the following contributions to the work: Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work. Drafting the work or revising it critically for important intellectual content. Final approval of the version to be published. Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Funding This work was funded in part by a Doctoral Research Fellowship for VK from the National Institute for Health Research. ME’s and SP’s research is supported by core funding from the United Kingdom’s National Institute of Health Research (NIHR) UCLH/UCL Biomedical Research Centre. SP’s research is also supported by the KCL/UCL Comprehensive Cancer Imaging Centre. During the trial, non-UK sites are funded to take part by the European Association of Urology Research Foundation (EaurF2015001).

Disclaimer The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health.

Competing interests ME has stock holding in NUADA Medical (as a founder member). NUADA Medical is a healthcare company specialising in urology and gynaecology. They provide a range of imaging services including MRI of the prostate. The other authors declare no competing interests.

Ethics approval NRES Committee East Midlands, Leicester.

Provenance and peer review Not commissioned; peer reviewed for ethical and funding approval prior to submission.

Data sharing statement All of the data for the trial protocol are included in the manuscript attached. No further data is present.

Open Access This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

REFERENCES
1. Center MM, Jernal A, Lortet-Tieulent J, et al. International variation in prostate cancer incidence and mortality rates. *Eur Urol* 2012;51:1079–92.
2. American Cancer society Prostate Cancer Key Statistics,. http://www.cancer.org/cancer/prostatecancer/detailedguide/prostate-cancer-key-statistics (accessed 1 Feb 2017).
3. Carter HB, Hamper UM, Sheth S, et al. Evaluation of transrectal ultrasound in the early detection of prostate cancer. *J Urol* 1989;142:1008–10.
4. Neveux P, Ouzzane A, Ahmed HU, et al. Quantitative tissue analyses of prostate cancer foci in an unselected cystoprostatectomy series. *BJU Int* 2012;110:517–23.
5. Ahmed HU, El-Shater Bosaily A, Brown LC, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. *The Lancet* 2017;389:815–22.
6. Schoots IG, Roobol MJ, Nieboer D, et al. Magnetic resonance imaging-targeted biopsy may enhance the diagnostic accuracy of significant prostate cancer detection compared to standard transrectal ultrasound-guided biopsy: a systematic review and meta-analysis. *Eur Urol* 2015;68:438–50.
7. Moore CM, Kasivisvanathan V, Eggener S, et al. Standards of reporting for MRI-targeted biopsy studies (START) of the prostate: recommendations from an International Working Group. *Eur Urol* 2013;64:544–52.
8. Dickinson L, Ahmed HU, Allen C, et al. Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting. *Eur Urol* 2011;59:477–94.
9. Weinreb JC, Barentsz JO, Choyke PL, et al. PI-RADS prostate Imaging - Reporting and Data System: 2015, version 2. *Eur Urol* 2016;69:16–40.
10. Undertaking a transrectal ultrasound guided biopsy of the prostate.. Public Health England Prostate Cancer Risk Management Programme guidelines, 2006. http://webarchive.nationalarchives.gov.uk/20150506150512/http://www.cancerscreening.nhs.uk/prostate/pcrmp01.pdf. (accessed 1 Feb 2017).
11. Kasivisvanathan V, DuFour R, Moore CM, et al. Transperineal magnetic resonance image targeted prostate biopsy versus transperineal template prostate biopsy in the detection of clinically significant prostate cancer. *J Urol* 2013;189:860–6.
12. Presti JC, O’Dowd GJ, Miller MC, et al. Extended peripheral zone biopsy schemes increase cancer detection rates and minimize variance in prostate specific antigen and age related cancer rates: results of a community multi-practice study. *J Urol* 2003;169:125–9.
13. EuroQol G. EuroQol—a new facility for the measurement of health-related quality of life. *Health Policy* 1990;16:199–208.
14. Rosario DJ, Lane JA, Metcalfe C, et al. Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study. *BMJ* 2012;344:d7894.